Adbry

Chemical Nametralokinumab-ldrm
Dosage FormInjection (subcutaneous; 150 mg/mL)
Drug ClassMonoclonal antibodies
SystemSkin
CompanyLEO Pharma
Approval Year2021

Indication

  • For the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
Last updated on 4/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Adbry (tralokinumab-ldrm) Prescribing Information.2021LEO Pharma Inc., Madison, NJ